Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro and animal experimental study with no human subjects.
PubMed 21040239 · doi:10.1111/j.1369-1600.2010.00251.x
What was done
The study tested whether the active metabolite noribogaine and the synthetic ibogaine derivative 18-methoxycoronaridine (18-MC) share ibogaine's mechanism of action on GDNF regulation and alcohol intake. GDNF mRNA expression was measured in SH-SY5Y cell culture following treatment with noribogaine or 18-MC. In addition, operant alcohol self-administration was evaluated in rats following targeted microinfusion of noribogaine or 18-MC into the ventral tegmental area (VTA).
What was found
The abstract reports no numerical values, effect sizes, or statistical figures. It reports directionally that noribogaine induced a robust increase in GDNF mRNA levels in SH-SY5Y cells, whereas 18-MC did not. In the rodent model, intra-VTA infusion of noribogaine significantly reduced operant responding for alcohol, while intra-VTA infusion of 18-MC had no effect.
Why it matters
The findings demonstrate that although both noribogaine and 18-MC exhibit anti-addictive profiles in rodents, they operate through divergent anatomical and molecular mechanisms: noribogaine reproduces ibogaine's VTA- and GDNF-mediated pathway, while 18-MC acts outside this specific mechanism.
Limits
The study is restricted to cell culture and rodent models, and findings cannot be directly extrapolated to clinical human pharmacotherapy. The abstract lacks specific sample sizes (n for cell assays or animals is not reported), dose-response ranges, exact effect sizes, and p-values. Non-VTA target regions and systemic off-target effects were not described.
Cited by
- supports Injecting ibogaine directly into the ventral tegmental area stops alcohol self-administration in rodents.